Method for the prognosis of survival time of a patient suffering from a solid cancer
AssigneesInserm (Institute National De La Sante Et De La Recherche Medicale), Universite Paris Descartes, Universite Pierre et Marie Curie (Paris6), Assistance Publique-Hopitaux de Paris
InventorsCatherine Sautes-Fridman, Wolf-Herve Fridman, Marie-Caroline Dieu-Nosjean, Jeremy Goc
Life of this patent
Estimating the term…
Abstract
The present invention relates to an in vitro method for the prognosis of survival of a patient suffering from a solid cancer, comprising the quantification of the cell density of CD8+ cells and DC-LAMP+ dendritic cells present in a tumor tissue sample from said patient, wherein a high density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has a favorable prognosis, a high density of CD8+ cells and a low density of DC-LAMP+ dendritic cells indicates that the patient has a poor prognosis, and a low density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has the worst prognosis.
Claims16
A method for treating a patient suffering from a solid cancer containing tumor-induced lymphoid structures, wherein said method comprises the following steps:
- a) quantifying, in a tumor tissue sample from said patient, the cell density of cluster of differentiation 8-positive (CD8+) cells;
- b) quantifying, in a tumor-induced lymphoid structure from said patient, the cell density of dendritic cell-lysosomal associated membrane protein positive (DC-LAMP+) dendritic cells;
- c) comparing cell density values obtained at step a) and b) with predetermined reference values for each type of cells at each location;
- and
- d) providing the patient with an adjuvant therapy when each of the cell density of CD8+ cells and DC-LAMP+ dendritic cells are lower than said predetermined reference values.
A method for treating a patient suffering from a solid cancer containing tumor-induced lymphoid structures, wherein said method comprises the following steps:
- a) quantifying, in a tumor tissue sample from said patient, the cell density of CD8+ cells;
- b) quantifying, in a tumor-induced lymphoid structure from said patient, the cell density of DC-LAMP+ dendritic cells;
- c) comparing cell density values obtained at step a) and b) with predetermined reference values for each type of cells at each location;
- and
- d) providing the patient with a cytotoxic agent when each of the cell density of CD8+ cells and DC-LAMP+ dendritic cells are lower than said predetermined reference values.
Dependencies are inferred from the claim text.